Market Cap | 4.84M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -12.55M | Forward P/E | -1.98 | EPS next Y | - | 50D Avg Chg | -19.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -73.00% |
Dividend | N/A | Price/Book | 0.48 | EPS next 5Y | - | 52W High Chg | -97.00% |
Recommedations | 2.00 | Quick Ratio | 0.29 | Shares Outstanding | 1.03M | 52W Low Chg | 7.00% |
Insider Own | 1.49% | ROA | -63.50% | Shares Float | 0.90M | Beta | 0.45 |
Inst Own | 6.39% | ROE | -398.58% | Shares Shorted/Prior | 60.58K/32.17K | Price | 0.91 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 362,385 | Target Price | - |
Oper. Margin | - | Earnings Date | Nov 7 | Volume | 42,665 | Change | -3.19% |
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
STEINMAN LAWRENCE | Director Director | Jun 01 | Buy | 1.226 | 18,000 | 22,068 | 48,129 | 06/02/23 |
McGovern Jr. Donald A. | Director Director | May 31 | Buy | 1.147 | 10,000 | 11,470 | 30,099 | 06/01/23 |
McGovern Jr. Donald A. | Director Director | May 18 | Buy | 1.11 | 15,000 | 16,650 | 20,099 | 05/22/23 |
Pamir Ozan | CFO CFO | May 18 | Buy | 1.01 | 5,162 | 5,214 | 8,983 | 05/19/23 |